First evidence that targeting tau may slow cognitive decline: diranersen tau ASO trial
Key Questions
What were the key findings from the diranersen tau ASO trial?
The Biogen/Ionis diranersen trial missed its primary endpoint but demonstrated strong tau PET reduction and cognitive slowing at the 60mg low dose, with 26% slowing on CDR-SB and 42% benefit on ADAS-Cog13. This marks the first evidence that targeting tau can slow cognitive decline.
Did the diranersen trial fully succeed, and what questions remain?
The trial showed promising signals at lower dosing despite missing the primary endpoint, raising questions about optimal dosing and reported confusion episodes. Results reinforce hope for tau therapies while highlighting the need for further optimization.
Why is the diranersen trial considered a milestone for Alzheimer's research?
It provides the first clinical evidence that tau-targeting can impact cognitive decline, shifting focus beyond amyloid and supporting continued development of antisense oligonucleotide approaches.
Biogen/Ionis diranersen (tau antisense oligonucleotide) missed primary endpoint but showed unprecedented tau PET reduction and cognitive slowing at low dose (60mg: 26% CDR-SB slowing, 42% ADAS-Cog13 benefit). Questions about confusion episodes and optimal dosing remain. This is the first evidence that targeting tau can slow cognitive decline, reinforcing hope while managing expectations. Results presented at recent conference.